Treatment initiation decisions in newly diagnosed epilepsy-A longitudinal cohort study.


Journal

Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R

Informations de publication

Date de publication:
03 2020
Historique:
received: 11 09 2019
revised: 08 01 2020
accepted: 08 01 2020
pubmed: 6 2 2020
medline: 21 10 2020
entrez: 6 2 2020
Statut: ppublish

Résumé

To examine the factors and reasons influencing treatment initiation decisions in patients with newly diagnosed epilepsy. We assessed antiseizure medication initiation decisions in adults with newly diagnosed epilepsy seen at first seizure clinics in Western Australia between 1999 and 2016 and followed to 2018. Of 610 patients (median age 40 years, 61.0% male), 426 (69.8%) were diagnosed after two or more seizures and 184 (30.2%) after a single seizure with risk factors for recurrence. Treatment was commenced in 427 patients (70.0%) at diagnosis, 112 (18.4%) during follow-up, mostly after further seizures, whereas 71 (11.6%) remained untreated at last follow-up. Elders (≥65 years, odds ratio [OR] = 3.06, 95% confidence interval [CI]: 1.62-5.80), more seizures (OR = 3.48, 95% CI: 2.03-5.96), and epileptogenic lesions on neuroimaging (OR = 2.15, 95% CI: 1.26-3.68) had a higher likelihood of treatment at diagnosis. Patients with less than one seizure per year within the preceding year (OR = 0.40, 95% CI: 0.21-0.73) and of higher socioeconomic status (OR = 0.985, 95% CI: 0.977-0.994) were less likely to be treated. For 93 patients (15.2%), treatment was not recommended at diagnosis, most commonly because only a single seizure had occurred. Ninety patients (14.8%) declined recommended treatment, mostly because they were unconvinced of the need for treatment or the diagnosis. Thirty percent of adults with newly diagnosed epilepsy were not immediately treated. Treatment initiation in this real-world cohort was influenced by age, number of seizures prior to diagnosis, imaging findings, patient preferences, and socioeconomic status.

Identifiants

pubmed: 32020603
doi: 10.1111/epi.16439
doi:

Substances chimiques

Anticonvulsants 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

445-454

Subventions

Organisme : UCB US
Pays : International

Informations de copyright

Wiley Periodicals, Inc. © 2020 International League Against Epilepsy.

Références

Ngugi AK, Kariuki SM, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Incidence of epilepsy: a systematic review and meta-analysis. Neurology. 2011;77:1005-12.
Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314-9.
Meyer AC, Dua T, Ma J, Saxena S, Birbeck G. Global disparities in the epilepsy treatment gap: a systematic review. Bull World Health Organ. 2010;88:260-6.
Meyer AC, Dua T, Boscardin WJ, Escarce JJ, Saxena S, Birbeck GL. Critical determinants of the epilepsy treatment gap: a cross-national analysis in resource-limited settings. Epilepsia. 2012;53:2178-85.
Mbuba CK, Ngugi AK, Newton CR, Carter JA. The epilepsy treatment gap in developing countries: a systematic review of the magnitude, causes, and intervention strategies. Epilepsia. 2008;49:1491-503.
Tian N, Boring M, Kobau R, Zack MM, Croft JB. Active epilepsy and seizure control in adults - United States, 2013 and 2015. MMWR Morb Mortal Wkly Rep. 2018;67:437-42.
Jallon P, Loiseau P, Loiseau J. Newly diagnosed unprovoked epileptic seizures: presentation at diagnosis in CAROLE study. Epilepsia. 2001;42:464-75.
Faught E, Helmers S, Thurman D, Kim H, Kalilani L. Patient characteristics and treatment patterns in patients with newly diagnosed epilepsy: a US database analysis. Epilepsy Behav. 2018;85:37-44.
Kalilani L, Faught E, Kim H, Burudpakdee C, Seetasith A, Laranjo S, et al. Assessment and effect of a gap between new-onset epilepsy diagnosis and treatment in the US. Neurology. 2019;92:e2197-e2208.
Marson A, Jacoby A, Johnson A, Kim L, Gamble C, Chadwick D. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet. 2005;365:2007-13.
Wiebe S. An immediate antiepileptic drug regimen reduced short-term (2-y) recurrence of seizures more than a deferred regimen. ACP Journ Club. 2005;143:75.
Kho LK, Lawn ND, Dunne JW, Linto J. First seizure presentation: do multiple seizures within 24 hours predict recurrence? Neurology. 2006;67:1047-9.
Fisher RS, Boas WVE, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46:470-2.
Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55:475-82.
Beretta S, Carone D, Zanchi C, Bianchi E, Pirovano M, Trentini C, et al. Long-term applicability of the new ILAE definition of epilepsy. Results from the PRO-LONG study. Epilepsia. 2017;58:1518-23.
Hakami T, Mcintosh A, Todaro M, Lui E, Yerra R, Tan KM, et al. MRI-identified pathology in adults with new-onset seizures. Neurology. 2013;81:920-7.
Ho K, Lawn N, Bynevelt M, Lee J, Dunne J. Neuroimaging of first-ever seizure: contribution of MRI if CT is normal. Neurol Clin Pract. 2013;3:398-403.
Tatum WO, Selioutski O, Ochoa JG, Clary HM, Cheek J, Drislane FW, et al. American clinical neurophysiology society guideline 7: guidelines for EEG reporting. Neurodiagn J. 2016;56:285-93.
Beghi E, Carpio A, Forsgren L, Hesdorffer DC, Malmgren K, Sander JW, et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia. 2010;51:671-5.
Australian Bureau of Statistics. 2033.0.55.001 - Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australia, Canberra, Australia, 2013. Available from: http://www.abs.gov.au/ausstats/abs@.nsf/mf/2033.0.55.001.
Lawn N, Chan J, Lee J, Dunne J. Is the first seizure epilepsy-and when? Epilepsia. 2015;56:1425-31.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research Electronic Data Capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377-81.
Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:512-21.
Kim LG, Johnson TL, Marson AG, Chadwick DW. Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial. Lancet Neurol. 2006;5:317-22.
Firth D. Bias reduction of maximum likelihood estimates. Biometrika. 1993;80:27-38.
Askamp J, van Putten MJ. Diagnostic decision-making after a first and recurrent seizure in adults. Seizure. 2013;22:507-11.
Hauser WA, Rich SS, Annegers JF, Anderson VE. Seizure recurrence after a 1st unprovoked seizure: an extended follow-up. Neurology. 1990;40:1163-70.
Chandramoulesswaran V, Dhanaraj M, Rangaraj R, Vengatesan A. Patients' preferences towards antiepileptic drug therapy following first attack of seizure. Neurol India. 2006;54:387-9.
Musicco M, Beghi E, Solari A, Viani F. Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. Neurology. 1997;49:991.
Leone MA, Giussani G, Nevitt SJ, Marson AG, Beghi E. Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure. Cochrane Database Syst Rev. 2016;CD007144. https://doi.org//10.1002/14651858
Nevitt SJ, Sudell M, Weston J, Tudur Smith C, Marson AG. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2017;12:Cd011412.
Jacoby A, Gamble C, Doughty J, Marson A, Chadwick D. Quality of life outcomes of immediate or delayed treatment of early epilepsy and single seizures. Neurology. 2007;68:1188-96.

Auteurs

Sameer Sharma (S)

Department of Neurosciences, Central Clinical School, Alfred Hospital, Monash University, Melbourne, Victoria, Australia.

Zhibin Chen (Z)

Department of Neurosciences, Central Clinical School, Alfred Hospital, Monash University, Melbourne, Victoria, Australia.
Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia.
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

Maria Rychkova (M)

Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia.

John Dunne (J)

School of Medicine, Royal Perth Hospital Unit, University of Western Australia, Perth, Western Australia, Australia.
WA Adult Epilepsy Service, Perth, Western Australia, Australia.

Judy Lee (J)

WA Adult Epilepsy Service, Perth, Western Australia, Australia.

Linda Kalilani (L)

UCB Pharma, Raleigh, NC, USA.

Nicholas Lawn (N)

WA Adult Epilepsy Service, Perth, Western Australia, Australia.

Patrick Kwan (P)

Department of Neurosciences, Central Clinical School, Alfred Hospital, Monash University, Melbourne, Victoria, Australia.
Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia.
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH